CN103179981B - 安全和功能性的人源化抗β‑淀粉样蛋白抗体 - Google Patents

Info

Publication number

CN103179981B

CN103179981B CN201180047312.2A CN201180047312A CN103179981B CN 103179981 B CN103179981 B CN 103179981B CN 201180047312 A CN201180047312 A CN 201180047312A CN 103179981 B CN103179981 B CN 103179981B

Authority

CN

China

Prior art keywords

antibody

beta

chain variable

amyloid

beta amyloid

Prior art date

2010-07-30

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Active

Links

• Espacenet
• Global Dossier
• Discuss

• 238000000034 method Methods 0.000 claims description 133
• 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims description 98
• 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 claims description 98
• 230000004913 activation Effects 0.000 claims description 78
• 238000012360 testing method Methods 0.000 claims description 78
• 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 75
• 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 75
• 230000000694 effects Effects 0.000 claims description 59
• 108090000623 proteins and genes Proteins 0.000 claims description 43
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 41
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 41
• 235000018102 proteins Nutrition 0.000 claims description 36
• 102000004169 proteins and genes Human genes 0.000 claims description 36
• 238000005259 measurement Methods 0.000 claims description 24
• 238000004113 cell culture Methods 0.000 claims description 18
• 239000012190 activator Substances 0.000 claims description 16
• 239000002253 acid Substances 0.000 claims description 15
• 238000001514 detection method Methods 0.000 claims description 12
• 230000000324 neuroprotective effect Effects 0.000 claims description 9
• 229920002472 Starch Polymers 0.000 claims description 8
• 238000010521 absorption reaction Methods 0.000 claims description 8
• 239000008107 starch Substances 0.000 claims description 8
• 235000019698 starch Nutrition 0.000 claims description 7
• 230000000295 complement effect Effects 0.000 claims description 6
• 102000004190 Enzymes Human genes 0.000 claims description 5
• 108090000790 Enzymes Proteins 0.000 claims description 5
• DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims description 5
• 108091000080 Phosphotransferase Proteins 0.000 claims description 3
• 102000020233 phosphotransferase Human genes 0.000 claims description 3
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 8
• 108010064539 amyloid beta-protein (1-42) Proteins 0.000 claims 1
• 238000002405 diagnostic procedure Methods 0.000 claims 1
• 238000011282 treatment Methods 0.000 abstract description 62
• 206010002022 amyloidosis Diseases 0.000 abstract description 30
• 208000024827 Alzheimer disease Diseases 0.000 abstract description 22
• 230000001225 therapeutic effect Effects 0.000 abstract description 9
• 102000009091 Amyloidogenic Proteins Human genes 0.000 abstract description 2
• 108010048112 Amyloidogenic Proteins Proteins 0.000 abstract description 2
• 208000035474 group of disease Diseases 0.000 abstract description 2
• 230000005856 abnormality Effects 0.000 abstract 1
• 210000004027 cell Anatomy 0.000 description 102
• 230000027455 binding Effects 0.000 description 52
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 48
• 238000009739 binding Methods 0.000 description 42
• 210000004556 brain Anatomy 0.000 description 42
• 239000012634 fragment Substances 0.000 description 42
• 201000010099 disease Diseases 0.000 description 41
• 241000699670 Mus sp. Species 0.000 description 33
• 239000000523 sample Substances 0.000 description 33
• 239000000427 antigen Substances 0.000 description 32
• 108091007433 antigens Proteins 0.000 description 32
• 102000036639 antigens Human genes 0.000 description 32
• 230000008569 process Effects 0.000 description 30
• 239000002609 medium Substances 0.000 description 29
• 238000002474 experimental method Methods 0.000 description 27
• 230000006870 function Effects 0.000 description 27
• 238000002372 labelling Methods 0.000 description 26
• 230000001054 cortical effect Effects 0.000 description 25
• 230000008859 change Effects 0.000 description 22
• 239000000203 mixture Substances 0.000 description 20
• 238000002965 ELISA Methods 0.000 description 19
• 235000001014 amino acid Nutrition 0.000 description 19
• 150000001413 amino acids Chemical class 0.000 description 19
• 125000000539 amino acid group Chemical group 0.000 description 18
• 238000002156 mixing Methods 0.000 description 18
• 210000002569 neuron Anatomy 0.000 description 18
• 241001465754 Metazoa Species 0.000 description 17
• 238000004043 dyeing Methods 0.000 description 17
• 108060003951 Immunoglobulin Proteins 0.000 description 16
• 238000003384 imaging method Methods 0.000 description 16
• 102000018358 immunoglobulin Human genes 0.000 description 16
• 239000002953 phosphate buffered saline Substances 0.000 description 16
• 238000002360 preparation method Methods 0.000 description 16
• 101150053137 AIF1 gene Proteins 0.000 description 15
• 206010012289 Dementia Diseases 0.000 description 15
• 241000700159 Rattus Species 0.000 description 15
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 15
• 102000004196 processed proteins & peptides Human genes 0.000 description 15
• 230000007850 degeneration Effects 0.000 description 14
• 239000012636 effector Substances 0.000 description 14
• 238000005516 engineering process Methods 0.000 description 14
• 229940121354 immunomodulator Drugs 0.000 description 14
• 229920001184 polypeptide Polymers 0.000 description 14
• 102000009109 Fc receptors Human genes 0.000 description 13
• 108010087819 Fc receptors Proteins 0.000 description 13
• 239000012642 immune effector Substances 0.000 description 13
• 239000000243 solution Substances 0.000 description 13
• 230000001988 toxicity Effects 0.000 description 13
• 231100000419 toxicity Toxicity 0.000 description 13
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 12
• 230000008499 blood brain barrier function Effects 0.000 description 12
• 210000001218 blood-brain barrier Anatomy 0.000 description 12
• 239000003153 chemical reaction reagent Substances 0.000 description 12
• 230000036039 immunity Effects 0.000 description 12
• 238000012545 processing Methods 0.000 description 12
• 230000001629 suppression Effects 0.000 description 12
• FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 11
• 241000699666 Mus <mouse, genus> Species 0.000 description 11
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 11
• 239000003814 drug Substances 0.000 description 11
• 230000009467 reduction Effects 0.000 description 11
• 230000009870 specific binding Effects 0.000 description 11
• 210000001519 tissue Anatomy 0.000 description 11
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
• 238000004458 analytical method Methods 0.000 description 10
• ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 10
• 238000002347 injection Methods 0.000 description 10
• 239000007924 injection Substances 0.000 description 10
• 102000005962 receptors Human genes 0.000 description 10
• 108020003175 receptors Proteins 0.000 description 10
• 230000004044 response Effects 0.000 description 10
• 201000009906 Meningitis Diseases 0.000 description 9
• 230000035508 accumulation Effects 0.000 description 9
• 238000009825 accumulation Methods 0.000 description 9
• 150000001875 compounds Chemical class 0.000 description 9
• 239000000975 dye Substances 0.000 description 9
• 239000003112 inhibitor Substances 0.000 description 9
• 239000002773 nucleotide Substances 0.000 description 9
• 125000003729 nucleotide group Chemical group 0.000 description 9
• 230000037361 pathway Effects 0.000 description 9
• 230000000770 proinflammatory effect Effects 0.000 description 9
• 238000011160 research Methods 0.000 description 9
• 206010029350 Neurotoxicity Diseases 0.000 description 8
• 206010030113 Oedema Diseases 0.000 description 8
• 206010044221 Toxic encephalopathy Diseases 0.000 description 8
• 230000003993 interaction Effects 0.000 description 8
• 230000004048 modification Effects 0.000 description 8
• 238000012986 modification Methods 0.000 description 8
• 210000004498 neuroglial cell Anatomy 0.000 description 8
• 230000003557 neuropsychological effect Effects 0.000 description 8
• 230000007135 neurotoxicity Effects 0.000 description 8
• 231100000228 neurotoxicity Toxicity 0.000 description 8
• 230000001575 pathological effect Effects 0.000 description 8
• 230000002265 prevention Effects 0.000 description 8
• 206010028980 Neoplasm Diseases 0.000 description 7
• 238000010171 animal model Methods 0.000 description 7
• 239000000872 buffer Substances 0.000 description 7
• 238000006243 chemical reaction Methods 0.000 description 7
• 210000001320 hippocampus Anatomy 0.000 description 7
• 238000003364 immunohistochemistry Methods 0.000 description 7
• 238000001727 in vivo Methods 0.000 description 7
• 238000012544 monitoring process Methods 0.000 description 7
• 230000007170 pathology Effects 0.000 description 7
• 230000002829 reductive effect Effects 0.000 description 7
• 230000019491 signal transduction Effects 0.000 description 7
• 230000004083 survival effect Effects 0.000 description 7
• 238000002560 therapeutic procedure Methods 0.000 description 7
• JADVWWSKYZXRGX-UHFFFAOYSA-M thioflavine T Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C1=[N+](C)C2=CC=C(C)C=C2S1 JADVWWSKYZXRGX-UHFFFAOYSA-M 0.000 description 7
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
• 108010060159 Apolipoprotein E4 Proteins 0.000 description 6
• 206010048962 Brain oedema Diseases 0.000 description 6
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
• 241000283984 Rodentia Species 0.000 description 6
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 6
• 238000000540 analysis of variance Methods 0.000 description 6
• 230000015572 biosynthetic process Effects 0.000 description 6
• 208000006752 brain edema Diseases 0.000 description 6
• 239000003795 chemical substances by application Substances 0.000 description 6
• 230000003013 cytotoxicity Effects 0.000 description 6
• 231100000135 cytotoxicity Toxicity 0.000 description 6
• ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 6
• 239000001963 growth medium Substances 0.000 description 6
• 238000003119 immunoblot Methods 0.000 description 6
• 238000003365 immunocytochemistry Methods 0.000 description 6
• JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
• 238000002595 magnetic resonance imaging Methods 0.000 description 6
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
• 230000006724 microglial activation Effects 0.000 description 6
• 239000000178 monomer Substances 0.000 description 6
• 238000006384 oligomerization reaction Methods 0.000 description 6
• 239000000546 pharmaceutical excipient Substances 0.000 description 6
• 229920000642 polymer Polymers 0.000 description 6
• 239000000843 powder Substances 0.000 description 6
• 238000007619 statistical method Methods 0.000 description 6
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
• -1 IL- 1st Proteins 0.000 description 5
• 108010073807 IgG Receptors Proteins 0.000 description 5
• 102000009490 IgG Receptors Human genes 0.000 description 5
• 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 5
• 208000012902 Nervous system disease Diseases 0.000 description 5
• 102000035195 Peptidases Human genes 0.000 description 5
• 108091005804 Peptidases Proteins 0.000 description 5
• XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 5
• 102100040247 Tumor necrosis factor Human genes 0.000 description 5
• 230000002776 aggregation Effects 0.000 description 5
• 238000004220 aggregation Methods 0.000 description 5
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 5
• 238000003556 assay Methods 0.000 description 5
• 210000004369 blood Anatomy 0.000 description 5
• 239000008280 blood Substances 0.000 description 5
• 238000004140 cleaning Methods 0.000 description 5
• 239000011248 coating agent Substances 0.000 description 5
• 238000000576 coating method Methods 0.000 description 5
• 238000007334 copolymerization reaction Methods 0.000 description 5
• 206010014599 encephalitis Diseases 0.000 description 5
• 230000004907 flux Effects 0.000 description 5
• 239000007788 liquid Substances 0.000 description 5
• 239000000463 material Substances 0.000 description 5
• 230000001404 mediated effect Effects 0.000 description 5
• 238000010172 mouse model Methods 0.000 description 5
• 210000005036 nerve Anatomy 0.000 description 5
• 210000000056 organ Anatomy 0.000 description 5
• 239000002243 precursor Substances 0.000 description 5
• 230000000750 progressive effect Effects 0.000 description 5
• 239000011780 sodium chloride Substances 0.000 description 5
• 239000000758 substrate Substances 0.000 description 5
• 208000024891 symptom Diseases 0.000 description 5
• 229960001685 tacrine Drugs 0.000 description 5
• YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 5
• 238000011830 transgenic mouse model Methods 0.000 description 5
• 238000010175 APPswe/PSEN1dE9 Methods 0.000 description 4
• 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 4
• 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 4
• 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 4
• 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 4
• 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 4
• 241000283707 Capra Species 0.000 description 4
• 201000010374 Down Syndrome Diseases 0.000 description 4
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
• 208000024781 Immune Complex disease Diseases 0.000 description 4
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 4
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 4
• 208000009829 Lewy Body Disease Diseases 0.000 description 4
• 201000002832 Lewy body dementia Diseases 0.000 description 4
• 206010025421 Macule Diseases 0.000 description 4
• 241000699660 Mus musculus Species 0.000 description 4
• 229930040373 Paraformaldehyde Natural products 0.000 description 4
• 206010033799 Paralysis Diseases 0.000 description 4
• 208000027089 Parkinsonian disease Diseases 0.000 description 4
• 206010034010 Parkinsonism Diseases 0.000 description 4
• 208000024777 Prion disease Diseases 0.000 description 4
• ZQUSFAUAYSEREK-WKILWMFISA-N SB-239063 Chemical compound COC1=NC=CC(C=2N(C=NC=2C=2C=CC(F)=CC=2)[C@@H]2CC[C@@H](O)CC2)=N1 ZQUSFAUAYSEREK-WKILWMFISA-N 0.000 description 4
• 206010044688 Trisomy 21 Diseases 0.000 description 4
• 239000000654 additive Substances 0.000 description 4
• 230000000996 additive effect Effects 0.000 description 4
• 238000013459 approach Methods 0.000 description 4
• 230000003542 behavioural effect Effects 0.000 description 4
• 238000001574 biopsy Methods 0.000 description 4
• 210000004899 c-terminal region Anatomy 0.000 description 4
• 230000003833 cell viability Effects 0.000 description 4
• 230000001413 cellular effect Effects 0.000 description 4
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 4
• 230000001149 cognitive effect Effects 0.000 description 4
• 210000003618 cortical neuron Anatomy 0.000 description 4
• 230000008021 deposition Effects 0.000 description 4
• 239000003085 diluting agent Substances 0.000 description 4
• 230000009977 dual effect Effects 0.000 description 4
• 239000000839 emulsion Substances 0.000 description 4
• 230000002124 endocrine Effects 0.000 description 4
• 230000002255 enzymatic effect Effects 0.000 description 4
• 229940088598 enzyme Drugs 0.000 description 4
• 238000011156 evaluation Methods 0.000 description 4
• 239000012530 fluid Substances 0.000 description 4
• 239000008103 glucose Substances 0.000 description 4
• 230000036541 health Effects 0.000 description 4
• 208000024326 hypersensitivity reaction type III disease Diseases 0.000 description 4
• 238000010166 immunofluorescence Methods 0.000 description 4
• 230000002163 immunogen Effects 0.000 description 4
• 238000000338 in vitro Methods 0.000 description 4
• 230000001965 increasing effect Effects 0.000 description 4
• 238000001990 intravenous administration Methods 0.000 description 4
• 239000002502 liposome Substances 0.000 description 4
• 230000027928 long-term synaptic potentiation Effects 0.000 description 4
• BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 4
• 230000015654 memory Effects 0.000 description 4
• 230000002503 metabolic effect Effects 0.000 description 4
• 201000006417 multiple sclerosis Diseases 0.000 description 4
• 230000035772 mutation Effects 0.000 description 4
• 229920002866 paraformaldehyde Polymers 0.000 description 4
• 239000008194 pharmaceutical composition Substances 0.000 description 4
• 238000012636 positron electron tomography Methods 0.000 description 4
• 230000002441 reversible effect Effects 0.000 description 4
• 239000013049 sediment Substances 0.000 description 4
• 241000894007 species Species 0.000 description 4
• 230000000638 stimulation Effects 0.000 description 4
• 239000006228 supernatant Substances 0.000 description 4
• 231100000331 toxic Toxicity 0.000 description 4
• 230000002588 toxic effect Effects 0.000 description 4
• 238000012549 training Methods 0.000 description 4
• 230000009261 transgenic effect Effects 0.000 description 4
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
• 208000025883 type III hypersensitivity disease Diseases 0.000 description 4
• UWSONZCNXUSTKW-UHFFFAOYSA-N 4,5-Dimethylthiazole Chemical compound CC=1N=CSC=1C UWSONZCNXUSTKW-UHFFFAOYSA-N 0.000 description 3
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
• 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 3
• 208000023769 AA amyloidosis Diseases 0.000 description 3
• 208000018282 ACys amyloidosis Diseases 0.000 description 3
• 206010065040 AIDS dementia complex Diseases 0.000 description 3
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• 208000002177 Cataract Diseases 0.000 description 3
• 208000005145 Cerebral amyloid angiopathy Diseases 0.000 description 3
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
• 208000007487 Familial Cerebral Amyloid Angiopathy Diseases 0.000 description 3
• 208000032849 Hereditary cerebral hemorrhage with amyloidosis Diseases 0.000 description 3
• 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 3
• 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 3
• 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 3
• 229930182555 Penicillin Natural products 0.000 description 3
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 239000004365 Protease Substances 0.000 description 3
• 108020004511 Recombinant DNA Proteins 0.000 description 3
• 206010039811 Secondary amyloidosis Diseases 0.000 description 3
• 230000002411 adverse Effects 0.000 description 3
• 229910021529 ammonia Inorganic materials 0.000 description 3
• 108010064397 amyloid beta-protein (1-40) Proteins 0.000 description 3
• 230000006933 amyloid-beta aggregation Effects 0.000 description 3
• 230000003110 anti-inflammatory effect Effects 0.000 description 3
• 230000000890 antigenic effect Effects 0.000 description 3
• 230000006399 behavior Effects 0.000 description 3
• 239000004305 biphenyl Substances 0.000 description 3
• 235000010290 biphenyl Nutrition 0.000 description 3
• 210000001124 body fluid Anatomy 0.000 description 3
• 239000010839 body fluid Substances 0.000 description 3
• 210000000988 bone and bone Anatomy 0.000 description 3
• 230000031709 bromination Effects 0.000 description 3
• 238000005893 bromination reaction Methods 0.000 description 3
• 244000309464 bull Species 0.000 description 3
• 230000007423 decrease Effects 0.000 description 3
• 238000003745 diagnosis Methods 0.000 description 3
• HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 3
• 239000000539 dimer Substances 0.000 description 3
• 238000010494 dissociation reaction Methods 0.000 description 3
• 230000005593 dissociations Effects 0.000 description 3
• 229960003530 donepezil Drugs 0.000 description 3
• 229940079593 drug Drugs 0.000 description 3
• 208000030533 eye disease Diseases 0.000 description 3
• 235000013305 food Nutrition 0.000 description 3
• 235000019253 formic acid Nutrition 0.000 description 3
• 239000011521 glass Substances 0.000 description 3
• 230000013595 glycosylation Effects 0.000 description 3
• 238000006206 glycosylation reaction Methods 0.000 description 3
• 230000000971 hippocampal effect Effects 0.000 description 3
• 230000002209 hydrophobic effect Effects 0.000 description 3
• 238000002649 immunization Methods 0.000 description 3
• 230000003053 immunization Effects 0.000 description 3
• 238000011503 in vivo imaging Methods 0.000 description 3
• 208000015181 infectious disease Diseases 0.000 description 3
• 230000003834 intracellular effect Effects 0.000 description 3
• 239000004310 lactic acid Substances 0.000 description 3
• 235000014655 lactic acid Nutrition 0.000 description 3
• 230000031700 light absorption Effects 0.000 description 3
• 150000002632 lipids Chemical class 0.000 description 3
• 239000003550 marker Substances 0.000 description 3
• 239000011159 matrix material Substances 0.000 description 3
• 201000011475 meningoencephalitis Diseases 0.000 description 3
• 210000000274 microglia Anatomy 0.000 description 3
• 230000032405 negative regulation of neuron apoptotic process Effects 0.000 description 3
• 210000002241 neurite Anatomy 0.000 description 3
• 108020004707 nucleic acids Proteins 0.000 description 3
• 102000039446 nucleic acids Human genes 0.000 description 3
• 150000007523 nucleic acids Chemical class 0.000 description 3
• 208000020911 optic nerve disease Diseases 0.000 description 3
• 229940049954 penicillin Drugs 0.000 description 3
• ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 3
• 210000002381 plasma Anatomy 0.000 description 3
• 239000013641 positive control Substances 0.000 description 3
• 238000002600 positron emission tomography Methods 0.000 description 3
• 239000000047 product Substances 0.000 description 3
• 238000000746 purification Methods 0.000 description 3
• 229960004136 rivastigmine Drugs 0.000 description 3
• 238000012216 screening Methods 0.000 description 3
• 238000001228 spectrum Methods 0.000 description 3
• 229960005322 streptomycin Drugs 0.000 description 3
• 238000013268 sustained release Methods 0.000 description 3
• 239000012730 sustained-release form Substances 0.000 description 3
• 150000003536 tetrazoles Chemical class 0.000 description 3
• 229940124597 therapeutic agent Drugs 0.000 description 3
• 238000012546 transfer Methods 0.000 description 3
• 230000007306 turnover Effects 0.000 description 3
• YKJYKKNCCRKFSL-RDBSUJKOSA-N (-)-anisomycin Chemical compound C1=CC(OC)=CC=C1C[C@@H]1[C@H](OC(C)=O)[C@@H](O)CN1 YKJYKKNCCRKFSL-RDBSUJKOSA-N 0.000 description 2
• NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
• YKJYKKNCCRKFSL-UHFFFAOYSA-N Anisomycin Natural products C1=CC(OC)=CC=C1CC1C(OC(C)=O)C(O)CN1 YKJYKKNCCRKFSL-UHFFFAOYSA-N 0.000 description 2
• 241000208340 Araliaceae Species 0.000 description 2
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
• 241000894006 Bacteria Species 0.000 description 2
• 206010007509 Cardiac amyloidosis Diseases 0.000 description 2
• 229940122041 Cholinesterase inhibitor Drugs 0.000 description 2
• 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 2
• 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 2
• 102100023033 Cyclic AMP-dependent transcription factor ATF-2 Human genes 0.000 description 2
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
• 108010021468 Fc gamma receptor IIA Proteins 0.000 description 2
• 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 2
• 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 2
• 208000032843 Hemorrhage Diseases 0.000 description 2
• 101000823051 Homo sapiens Amyloid-beta precursor protein Proteins 0.000 description 2
• 101000974934 Homo sapiens Cyclic AMP-dependent transcription factor ATF-2 Proteins 0.000 description 2
• 101000997829 Homo sapiens Glial cell line-derived neurotrophic factor Proteins 0.000 description 2
• 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 2
• 101000944909 Homo sapiens Ribosomal protein S6 kinase alpha-1 Proteins 0.000 description 2
• 101000945090 Homo sapiens Ribosomal protein S6 kinase alpha-3 Proteins 0.000 description 2
• 101000945096 Homo sapiens Ribosomal protein S6 kinase alpha-5 Proteins 0.000 description 2
• 108010073816 IgE Receptors Proteins 0.000 description 2
• 206010061218 Inflammation Diseases 0.000 description 2
• 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 description 2
• 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 2
• 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 2
• 102100026299 MAP kinase-interacting serine/threonine-protein kinase 1 Human genes 0.000 description 2
• 101710139011 MAP kinase-interacting serine/threonine-protein kinase 1 Proteins 0.000 description 2
• 241001597008 Nomeidae Species 0.000 description 2
• 206010061323 Optic neuropathy Diseases 0.000 description 2
• 239000012826 P38 inhibitor Substances 0.000 description 2
• 238000012879 PET imaging Methods 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
• 235000003140 Panax quinquefolius Nutrition 0.000 description 2
• 102000057297 Pepsin A Human genes 0.000 description 2
• 108090000284 Pepsin A Proteins 0.000 description 2
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
• 108010039918 Polylysine Proteins 0.000 description 2
• 102100022033 Presenilin-1 Human genes 0.000 description 2
• 102000015499 Presenilins Human genes 0.000 description 2
• 108010050254 Presenilins Proteins 0.000 description 2
• 241000288906 Primates Species 0.000 description 2
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
• 102100033536 Ribosomal protein S6 kinase alpha-1 Human genes 0.000 description 2
• 102100033643 Ribosomal protein S6 kinase alpha-3 Human genes 0.000 description 2
• 102100033645 Ribosomal protein S6 kinase alpha-5 Human genes 0.000 description 2
• 108010017324 STAT3 Transcription Factor Proteins 0.000 description 2
• 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 2
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
• 102000004874 Synaptophysin Human genes 0.000 description 2
• 108090001076 Synaptophysin Proteins 0.000 description 2
• 108700019146 Transgenes Proteins 0.000 description 2
• 239000013504 Triton X-100 Substances 0.000 description 2
• 229920004890 Triton X-100 Polymers 0.000 description 2
• 102000004243 Tubulin Human genes 0.000 description 2
• 108090000704 Tubulin Proteins 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• 230000002159 abnormal effect Effects 0.000 description 2
• 230000009471 action Effects 0.000 description 2
• 230000003213 activating effect Effects 0.000 description 2
• 239000000443 aerosol Substances 0.000 description 2
• GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 2
• 230000003941 amyloidogenesis Effects 0.000 description 2
• 230000001405 anti-neuronal effect Effects 0.000 description 2
• 239000007864 aqueous solution Substances 0.000 description 2
• 229940039856 aricept Drugs 0.000 description 2
• 229950001863 bapineuzumab Drugs 0.000 description 2
• 230000006736 behavioral deficit Effects 0.000 description 2
• IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• 230000000740 bleeding effect Effects 0.000 description 2
• 230000000903 blocking effect Effects 0.000 description 2
• 210000004204 blood vessel Anatomy 0.000 description 2
• 238000000423 cell based assay Methods 0.000 description 2
• 239000006143 cell culture medium Substances 0.000 description 2
• 210000000170 cell membrane Anatomy 0.000 description 2
• 239000006285 cell suspension Substances 0.000 description 2
• 208000037976 chronic inflammation Diseases 0.000 description 2
• 230000019771 cognition Effects 0.000 description 2
• 230000007278 cognition impairment Effects 0.000 description 2
• 230000003930 cognitive ability Effects 0.000 description 2
• 208000010877 cognitive disease Diseases 0.000 description 2
• 230000000052 comparative effect Effects 0.000 description 2
• 239000002131 composite material Substances 0.000 description 2
• 238000002591 computed tomography Methods 0.000 description 2
• 239000003636 conditioned culture medium Substances 0.000 description 2
• 230000004891 conditioned taste aversion Effects 0.000 description 2
• 235000009508 confectionery Nutrition 0.000 description 2
• IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 2
• 229920001577 copolymer Polymers 0.000 description 2
• 231100000433 cytotoxic Toxicity 0.000 description 2
• 230000001472 cytotoxic effect Effects 0.000 description 2
• 230000006866 deterioration Effects 0.000 description 2
• 238000011161 development Methods 0.000 description 2
• 230000018109 developmental process Effects 0.000 description 2
• 230000029087 digestion Effects 0.000 description 2
• 239000012470 diluted sample Substances 0.000 description 2
• 231100000673 dose–response relationship Toxicity 0.000 description 2
• 239000000890 drug combination Substances 0.000 description 2
• 235000013399 edible fruits Nutrition 0.000 description 2
• 235000013601 eggs Nutrition 0.000 description 2
• 229940108366 exelon Drugs 0.000 description 2
• 239000000835 fiber Substances 0.000 description 2
• 239000012467 final product Substances 0.000 description 2
• 238000007667 floating Methods 0.000 description 2
• 229960003980 galantamine Drugs 0.000 description 2
• ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 2
• 235000008434 ginseng Nutrition 0.000 description 2
• 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 2
• 239000003292 glue Substances 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 210000003714 granulocyte Anatomy 0.000 description 2
• 230000012010 growth Effects 0.000 description 2
• 238000003306 harvesting Methods 0.000 description 2
• ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 2
• 210000003630 histaminocyte Anatomy 0.000 description 2
• 102000046783 human APP Human genes 0.000 description 2
• 210000004408 hybridoma Anatomy 0.000 description 2
• 230000001900 immune effect Effects 0.000 description 2
• 230000028993 immune response Effects 0.000 description 2
• 230000005847 immunogenicity Effects 0.000 description 2
• 230000001976 improved effect Effects 0.000 description 2
• 201000008319 inclusion body myositis Diseases 0.000 description 2
• 230000004968 inflammatory condition Effects 0.000 description 2
• 230000002757 inflammatory effect Effects 0.000 description 2
• 230000004054 inflammatory process Effects 0.000 description 2
• 230000002401 inhibitory effect Effects 0.000 description 2
• 230000007154 intracellular accumulation Effects 0.000 description 2
• 238000010253 intravenous injection Methods 0.000 description 2
• 230000013016 learning Effects 0.000 description 2
• KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
• 230000033001 locomotion Effects 0.000 description 2
• 238000009593 lumbar puncture Methods 0.000 description 2
• 210000004698 lymphocyte Anatomy 0.000 description 2
• 210000002540 macrophage Anatomy 0.000 description 2
• 238000013507 mapping Methods 0.000 description 2
• 230000007246 mechanism Effects 0.000 description 2
• 229960004640 memantine Drugs 0.000 description 2
• 230000007087 memory ability Effects 0.000 description 2
• 210000002418 meninge Anatomy 0.000 description 2
• GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 2
• 208000027061 mild cognitive impairment Diseases 0.000 description 2
• 230000002438 mitochondrial effect Effects 0.000 description 2
• 229940033872 namenda Drugs 0.000 description 2
• 210000000822 natural killer cell Anatomy 0.000 description 2
• 230000002887 neurotoxic effect Effects 0.000 description 2
• 239000002858 neurotransmitter agent Substances 0.000 description 2
• 230000007935 neutral effect Effects 0.000 description 2
• 238000006386 neutralization reaction Methods 0.000 description 2
• 230000003448 neutrophilic effect Effects 0.000 description 2
• 238000009206 nuclear medicine Methods 0.000 description 2
• 230000003287 optical effect Effects 0.000 description 2
• 230000003647 oxidation Effects 0.000 description 2
• 238000007254 oxidation reaction Methods 0.000 description 2
• 239000012188 paraffin wax Substances 0.000 description 2
• 239000002245 particle Substances 0.000 description 2
• 230000007918 pathogenicity Effects 0.000 description 2
• 231100000915 pathological change Toxicity 0.000 description 2
• 230000036285 pathological change Effects 0.000 description 2
• 229940111202 pepsin Drugs 0.000 description 2
• 230000006919 peptide aggregation Effects 0.000 description 2
• 230000035699 permeability Effects 0.000 description 2
• 230000026731 phosphorylation Effects 0.000 description 2
• 238000006366 phosphorylation reaction Methods 0.000 description 2
• 238000000053 physical method Methods 0.000 description 2
• 239000006187 pill Substances 0.000 description 2
• 210000002706 plastid Anatomy 0.000 description 2
• 231100000614 poison Toxicity 0.000 description 2
• 229920000656 polylysine Polymers 0.000 description 2
• 235000019419 proteases Nutrition 0.000 description 2
• 230000001681 protective effect Effects 0.000 description 2
• 230000002285 radioactive effect Effects 0.000 description 2
• 239000000700 radioactive tracer Substances 0.000 description 2
• 230000006798 recombination Effects 0.000 description 2
• 238000005215 recombination Methods 0.000 description 2
• 230000000630 rising effect Effects 0.000 description 2
• 238000007789 sealing Methods 0.000 description 2
• 238000001338 self-assembly Methods 0.000 description 2
• 210000002966 serum Anatomy 0.000 description 2
• 210000003491 skin Anatomy 0.000 description 2
• 210000003625 skull Anatomy 0.000 description 2
• 229950007874 solanezumab Drugs 0.000 description 2
• 239000007787 solid Substances 0.000 description 2
• 238000010561 standard procedure Methods 0.000 description 2
• 230000004936 stimulating effect Effects 0.000 description 2
• 239000000126 substance Substances 0.000 description 2
• 235000000346 sugar Nutrition 0.000 description 2
• 238000003786 synthesis reaction Methods 0.000 description 2
• 238000003325 tomography Methods 0.000 description 2
• 238000013519 translation Methods 0.000 description 2
• IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 2
• 230000002792 vascular Effects 0.000 description 2
• 230000000982 vasogenic effect Effects 0.000 description 2
• 239000003981 vehicle Substances 0.000 description 2
• 230000000007 visual effect Effects 0.000 description 2
• SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
• KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
• LZXHHNKULPHARO-UHFFFAOYSA-M (3,4-dichlorophenyl)methyl-triphenylphosphanium;chloride Chemical compound [Cl-].C1=C(Cl)C(Cl)=CC=C1C[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 LZXHHNKULPHARO-UHFFFAOYSA-M 0.000 description 1
• WOAHJDHKFWSLKE-UHFFFAOYSA-N 1,2-benzoquinone Chemical compound O=C1C=CC=CC1=O WOAHJDHKFWSLKE-UHFFFAOYSA-N 0.000 description 1
• ALLIZEAXNXSFGD-UHFFFAOYSA-N 1-methyl-2-phenylbenzene Chemical group CC1=CC=CC=C1C1=CC=CC=C1 ALLIZEAXNXSFGD-UHFFFAOYSA-N 0.000 description 1
• IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• ZQAQXZBSGZUUNL-BJUDXGSMSA-N 2-[4-(methylamino)phenyl]-1,3-benzothiazol-6-ol Chemical compound C1=CC(N[11CH3])=CC=C1C1=NC2=CC=C(O)C=C2S1 ZQAQXZBSGZUUNL-BJUDXGSMSA-N 0.000 description 1
• CVOFKRWYWCSDMA-UHFFFAOYSA-N 2-chloro-n-(2,6-diethylphenyl)-n-(methoxymethyl)acetamide;2,6-dinitro-n,n-dipropyl-4-(trifluoromethyl)aniline Chemical compound CCC1=CC=CC(CC)=C1N(COC)C(=O)CCl.CCCN(CCC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O CVOFKRWYWCSDMA-UHFFFAOYSA-N 0.000 description 1
• SNKZJIOFVMKAOJ-UHFFFAOYSA-N 3-Amino-1-propanesulfonic acid Natural products NCCCS(O)(=O)=O SNKZJIOFVMKAOJ-UHFFFAOYSA-N 0.000 description 1
• QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
• QUTYKIXIUDQOLK-PRJMDXOYSA-N 5-O-(1-carboxyvinyl)-3-phosphoshikimic acid Chemical compound O[C@H]1[C@H](OC(=C)C(O)=O)CC(C(O)=O)=C[C@H]1OP(O)(O)=O QUTYKIXIUDQOLK-PRJMDXOYSA-N 0.000 description 1
• LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
• 208000023761 AL amyloidosis Diseases 0.000 description 1
• 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
• 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
• 102100034112 Alkyldihydroxyacetonephosphate synthase, peroxisomal Human genes 0.000 description 1
• 102000001049 Amyloid Human genes 0.000 description 1
• 108010094108 Amyloid Proteins 0.000 description 1
• 208000037259 Amyloid Plaque Diseases 0.000 description 1
• 206010002023 Amyloidoses Diseases 0.000 description 1
• 206010002091 Anaesthesia Diseases 0.000 description 1
• 102000006306 Antigen Receptors Human genes 0.000 description 1
• 108010083359 Antigen Receptors Proteins 0.000 description 1
• 108010025628 Apolipoproteins E Proteins 0.000 description 1
• 102000013918 Apolipoproteins E Human genes 0.000 description 1
• 241000239290 Araneae Species 0.000 description 1
• CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
• 235000010894 Artemisia argyi Nutrition 0.000 description 1
• 206010063659 Aversion Diseases 0.000 description 1
• 230000006974 Aβ toxicity Effects 0.000 description 1
• 102400000967 Bradykinin Human genes 0.000 description 1
• 101800004538 Bradykinin Proteins 0.000 description 1
• UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
• 241000282461 Canis lupus Species 0.000 description 1
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
• 102000014914 Carrier Proteins Human genes 0.000 description 1
• 108010078791 Carrier Proteins Proteins 0.000 description 1
• 102000011068 Cdc42 Human genes 0.000 description 1
• 108050001278 Cdc42 Proteins 0.000 description 1
• 241000282693 Cercopithecidae Species 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 241000557626 Corvus corax Species 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• 102000004127 Cytokines Human genes 0.000 description 1
• 108090000695 Cytokines Proteins 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• 108020004414 DNA Proteins 0.000 description 1
• 230000033616 DNA repair Effects 0.000 description 1
• 241001269238 Data Species 0.000 description 1
• 102000016911 Deoxyribonucleases Human genes 0.000 description 1
• 108010053770 Deoxyribonucleases Proteins 0.000 description 1
• YWHLKYXPLRWGSE-UHFFFAOYSA-N Dimethyl trisulfide Chemical compound CSSSC YWHLKYXPLRWGSE-UHFFFAOYSA-N 0.000 description 1
• 238000008157 ELISA kit Methods 0.000 description 1
• 102000002322 Egg Proteins Human genes 0.000 description 1
• 108010000912 Egg Proteins Proteins 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 241000196324 Embryophyta Species 0.000 description 1
• 208000004232 Enteritis Diseases 0.000 description 1
• 101710204837 Envelope small membrane protein Proteins 0.000 description 1
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
• 206010016202 Familial Amyloidosis Diseases 0.000 description 1
• 206010016207 Familial Mediterranean fever Diseases 0.000 description 1
• 108010021472 Fc gamma receptor IIB Proteins 0.000 description 1
• 208000033694 Generalised erythema Diseases 0.000 description 1
• 235000011201 Ginkgo Nutrition 0.000 description 1
• 244000194101 Ginkgo biloba Species 0.000 description 1
• 235000008100 Ginkgo biloba Nutrition 0.000 description 1
• 208000010412 Glaucoma Diseases 0.000 description 1
• 102000006395 Globulins Human genes 0.000 description 1
• 108010044091 Globulins Proteins 0.000 description 1
• 102000005720 Glutathione transferase Human genes 0.000 description 1
• 108010070675 Glutathione transferase Proteins 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 229920002683 Glycosaminoglycan Polymers 0.000 description 1
• QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
• 239000007995 HEPES buffer Substances 0.000 description 1
• 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
• 101000799143 Homo sapiens Alkyldihydroxyacetonephosphate synthase, peroxisomal Proteins 0.000 description 1
• 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
• 101000878602 Homo sapiens Immunoglobulin alpha Fc receptor Proteins 0.000 description 1
• 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 description 1
• 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
• 101001092197 Homo sapiens RNA binding protein fox-1 homolog 3 Proteins 0.000 description 1
• 101000674731 Homo sapiens TGF-beta-activated kinase 1 and MAP3K7-binding protein 1 Proteins 0.000 description 1
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
• 102000009438 IgE Receptors Human genes 0.000 description 1
• 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 1
• 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
• 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
• 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
• 208000005531 Immunoglobulin Light-chain Amyloidosis Diseases 0.000 description 1
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
• 102100038005 Immunoglobulin alpha Fc receptor Human genes 0.000 description 1
• 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
• 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• 229930182816 L-glutamine Natural products 0.000 description 1
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
• 102000007330 LDL Lipoproteins Human genes 0.000 description 1
• 108010007622 LDL Lipoproteins Proteins 0.000 description 1
• 241001484259 Lacuna Species 0.000 description 1
• 241000446313 Lamella Species 0.000 description 1
• 206010024229 Leprosy Diseases 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• 102100029205 Low affinity immunoglobulin gamma Fc region receptor II-b Human genes 0.000 description 1
• LUWJPTVQOMUZLW-UHFFFAOYSA-N Luxol fast blue MBS Chemical compound [Cu++].Cc1ccccc1N\C(N)=N\c1ccccc1C.Cc1ccccc1N\C(N)=N\c1ccccc1C.OS(=O)(=O)c1cccc2c3nc(nc4nc([n-]c5[n-]c(nc6nc(n3)c3ccccc63)c3c(cccc53)S(O)(=O)=O)c3ccccc43)c12 LUWJPTVQOMUZLW-UHFFFAOYSA-N 0.000 description 1
• 241000124008 Mammalia Species 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 206010027236 Meningitis fungal Diseases 0.000 description 1
• 102000005431 Molecular Chaperones Human genes 0.000 description 1
• 108010006519 Molecular Chaperones Proteins 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
• 206010029240 Neuritis Diseases 0.000 description 1
• 239000000020 Nitrocellulose Substances 0.000 description 1
• 208000022873 Ocular disease Diseases 0.000 description 1
• 208000009702 Optic Disk Drusen Diseases 0.000 description 1
• 208000003435 Optic Neuritis Diseases 0.000 description 1
• 241000283973 Oryctolagus cuniculus Species 0.000 description 1
• 101700056750 PAK1 Proteins 0.000 description 1
• 102100026466 POU domain, class 2, transcription factor 3 Human genes 0.000 description 1
• 101710084413 POU domain, class 2, transcription factor 3 Proteins 0.000 description 1
• 241000282577 Pan troglodytes Species 0.000 description 1
• 108090000526 Papain Proteins 0.000 description 1
• 208000037581 Persistent Infection Diseases 0.000 description 1
• 206010057249 Phagocytosis Diseases 0.000 description 1
• BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
• 229920002732 Polyanhydride Polymers 0.000 description 1
• 241000201976 Polycarpon Species 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 229920001213 Polysorbate 20 Polymers 0.000 description 1
• 102000004257 Potassium Channel Human genes 0.000 description 1
• 102000012412 Presenilin-1 Human genes 0.000 description 1
• 108010036933 Presenilin-1 Proteins 0.000 description 1
• 206010036673 Primary amyloidosis Diseases 0.000 description 1
• RBQOQRRFDPXAGN-UHFFFAOYSA-N Propentofylline Chemical compound CN1C(=O)N(CCCCC(C)=O)C(=O)C2=C1N=CN2CCC RBQOQRRFDPXAGN-UHFFFAOYSA-N 0.000 description 1
• 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
• 102100035530 RNA binding protein fox-1 homolog 3 Human genes 0.000 description 1
• 101000648290 Rattus norvegicus Tumor necrosis factor Proteins 0.000 description 1
• 101710088839 Replication initiation protein Proteins 0.000 description 1
• 240000000111 Saccharum officinarum Species 0.000 description 1
• 235000007201 Saccharum officinarum Nutrition 0.000 description 1
• 102100031206 Serine/threonine-protein kinase N1 Human genes 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• 206010040943 Skin Ulcer Diseases 0.000 description 1
• PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 1
• PJANXHGTPQOBST-VAWYXSNFSA-N Stilbene Natural products C=1C=CC=CC=1/C=C/C1=CC=CC=C1 PJANXHGTPQOBST-VAWYXSNFSA-N 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 239000005864 Sulphur Substances 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• 102100021228 TGF-beta-activated kinase 1 and MAP3K7-binding protein 1 Human genes 0.000 description 1
• 102000003714 TNF receptor-associated factor 6 Human genes 0.000 description 1
• 108090000009 TNF receptor-associated factor 6 Proteins 0.000 description 1
• 239000007983 Tris buffer Substances 0.000 description 1
• 102000004142 Trypsin Human genes 0.000 description 1
• 108090000631 Trypsin Proteins 0.000 description 1
• 206010047115 Vasculitis Diseases 0.000 description 1
• 229930003779 Vitamin B12 Natural products 0.000 description 1
• 235000009392 Vitis Nutrition 0.000 description 1
• 241000219095 Vitis Species 0.000 description 1
• SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
• OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
• 229960004373 acetylcholine Drugs 0.000 description 1
• 230000001154 acute effect Effects 0.000 description 1
• 208000038016 acute inflammation Diseases 0.000 description 1
• 230000006022 acute inflammation Effects 0.000 description 1
• 230000003044 adaptive effect Effects 0.000 description 1
• 230000032683 aging Effects 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• CKMXBZGNNVIXHC-UHFFFAOYSA-L ammonium magnesium phosphate hexahydrate Chemical compound [NH4+].O.O.O.O.O.O.[Mg+2].[O-]P([O-])([O-])=O CKMXBZGNNVIXHC-UHFFFAOYSA-L 0.000 description 1
• 230000037005 anaesthesia Effects 0.000 description 1
• 238000000848 angular dependent Auger electron spectroscopy Methods 0.000 description 1
• 230000002424 anti-apoptotic effect Effects 0.000 description 1
• 230000000844 anti-bacterial effect Effects 0.000 description 1
• 230000000845 anti-microbial effect Effects 0.000 description 1
• 230000009830 antibody antigen interaction Effects 0.000 description 1
• 230000005875 antibody response Effects 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 230000003078 antioxidant effect Effects 0.000 description 1
• 239000003125 aqueous solvent Substances 0.000 description 1
• 229910052786 argon Inorganic materials 0.000 description 1
• 229960004372 aripiprazole Drugs 0.000 description 1
• 244000030166 artemisia Species 0.000 description 1
• 238000000429 assembly Methods 0.000 description 1
• 230000000712 assembly Effects 0.000 description 1
• 210000001130 astrocyte Anatomy 0.000 description 1
• 239000005667 attractant Substances 0.000 description 1
• 239000003693 atypical antipsychotic agent Substances 0.000 description 1
• 229940127236 atypical antipsychotics Drugs 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 208000013404 behavioral symptom Diseases 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 1
• 230000001588 bifunctional effect Effects 0.000 description 1
• 229920002988 biodegradable polymer Polymers 0.000 description 1
• 239000004621 biodegradable polymer Substances 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 230000006287 biotinylation Effects 0.000 description 1
• 238000007413 biotinylation Methods 0.000 description 1
• 230000017531 blood circulation Effects 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 239000005388 borosilicate glass Substances 0.000 description 1
• QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
• 210000004958 brain cell Anatomy 0.000 description 1
• 238000009395 breeding Methods 0.000 description 1
• 230000001488 breeding effect Effects 0.000 description 1
• 239000007853 buffer solution Substances 0.000 description 1
• 230000003139 buffering effect Effects 0.000 description 1
• 239000001110 calcium chloride Substances 0.000 description 1
• 229910001628 calcium chloride Inorganic materials 0.000 description 1
• 201000011510 cancer Diseases 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
• 230000001925 catabolic effect Effects 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 239000008004 cell lysis buffer Substances 0.000 description 1
• 230000005754 cellular signaling Effects 0.000 description 1
• 230000007541 cellular toxicity Effects 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• 238000005119 centrifugation Methods 0.000 description 1
• 230000002490 cerebral effect Effects 0.000 description 1
• 230000031902 chemoattractant activity Effects 0.000 description 1
• 229960001231 choline Drugs 0.000 description 1
• OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
• 239000000544 cholinesterase inhibitor Substances 0.000 description 1
• 230000001684 chronic effect Effects 0.000 description 1
• 230000006020 chronic inflammation Effects 0.000 description 1
• 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
• 230000006720 chronic neuroinflammation Effects 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 229960004170 clozapine Drugs 0.000 description 1
• QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
• 238000011278 co-treatment Methods 0.000 description 1
• AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
• 230000003920 cognitive function Effects 0.000 description 1
• 230000006998 cognitive state Effects 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 230000024203 complement activation Effects 0.000 description 1
• 230000003750 conditioning effect Effects 0.000 description 1
• 210000002808 connective tissue Anatomy 0.000 description 1
• 108091036078 conserved sequence Proteins 0.000 description 1
• 239000006071 cream Substances 0.000 description 1
• 238000004132 cross linking Methods 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 238000005520 cutting process Methods 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• 230000009089 cytolysis Effects 0.000 description 1
• 230000001120 cytoprotective effect Effects 0.000 description 1
• 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
• 238000000354 decomposition reaction Methods 0.000 description 1
• 238000005034 decoration Methods 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000007812 deficiency Effects 0.000 description 1
• 230000002950 deficient Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 238000005238 degreasing Methods 0.000 description 1
• 210000001947 dentate gyrus Anatomy 0.000 description 1
• 230000001419 dependent effect Effects 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• 238000003748 differential diagnosis Methods 0.000 description 1
• ATUOYWHBWRKTHZ-UHFFFAOYSA-N dimethylmethane Natural products CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 1
• 230000008034 disappearance Effects 0.000 description 1
• 229910000397 disodium phosphate Inorganic materials 0.000 description 1
• 208000035475 disorder Diseases 0.000 description 1
• 238000009826 distribution Methods 0.000 description 1
• 239000006196 drop Substances 0.000 description 1
• 238000013535 dynamic contrast enhanced MRI Methods 0.000 description 1
• 235000014103 egg white Nutrition 0.000 description 1
• 210000000969 egg white Anatomy 0.000 description 1
• 238000001378 electrochemiluminescence detection Methods 0.000 description 1
• 239000003792 electrolyte Substances 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 230000008451 emotion Effects 0.000 description 1
• 210000003038 endothelium Anatomy 0.000 description 1
• 238000012407 engineering method Methods 0.000 description 1
• 230000009483 enzymatic pathway Effects 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 239000000284 extract Substances 0.000 description 1
• 239000003889 eye drop Substances 0.000 description 1
• 229940012356 eye drops Drugs 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 239000006052 feed supplement Substances 0.000 description 1
• 230000001605 fetal effect Effects 0.000 description 1
• MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
• 238000009472 formulation Methods 0.000 description 1
• 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
• 238000011990 functional testing Methods 0.000 description 1
• 201000010056 fungal meningitis Diseases 0.000 description 1
• 230000004927 fusion Effects 0.000 description 1
• 108020001507 fusion proteins Proteins 0.000 description 1
• 102000037865 fusion proteins Human genes 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 239000000499 gel Substances 0.000 description 1
• 238000002523 gelfiltration Methods 0.000 description 1
• 229940084910 gliadel Drugs 0.000 description 1
• 239000003862 glucocorticoid Substances 0.000 description 1
• 229930195712 glutamate Natural products 0.000 description 1
• 150000004676 glycans Chemical class 0.000 description 1
• 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
• 239000010931 gold Substances 0.000 description 1
• 229910052737 gold Inorganic materials 0.000 description 1
• 239000011544 gradient gel Substances 0.000 description 1
• 210000004884 grey matter Anatomy 0.000 description 1
• 210000004247 hand Anatomy 0.000 description 1
• 208000017105 hereditary amyloidosis Diseases 0.000 description 1
• 239000000833 heterodimer Substances 0.000 description 1
• 238000004128 high performance liquid chromatography Methods 0.000 description 1
• 210000004295 hippocampal neuron Anatomy 0.000 description 1
• 229920001519 homopolymer Polymers 0.000 description 1
• 102000053391 human F Human genes 0.000 description 1
• 108700031895 human F Proteins 0.000 description 1
• 229920002674 hyaluronan Polymers 0.000 description 1
• 229960003160 hyaluronic acid Drugs 0.000 description 1
• 210000004754 hybrid cell Anatomy 0.000 description 1
• 230000007062 hydrolysis Effects 0.000 description 1
• 238000006460 hydrolysis reaction Methods 0.000 description 1
• 125000001165 hydrophobic group Chemical group 0.000 description 1
• 239000012216 imaging agent Substances 0.000 description 1
• 238000003018 immunoassay Methods 0.000 description 1
• 229940072221 immunoglobulins Drugs 0.000 description 1
• 238000011532 immunohistochemical staining Methods 0.000 description 1
• 239000002955 immunomodulating agent Substances 0.000 description 1
• 230000002584 immunomodulator Effects 0.000 description 1
• 238000009169 immunotherapy Methods 0.000 description 1
• 238000002513 implantation Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 238000003780 insertion Methods 0.000 description 1
• 230000037431 insertion Effects 0.000 description 1
• 238000007689 inspection Methods 0.000 description 1
• 238000001361 intraarterial administration Methods 0.000 description 1
• 238000007917 intracranial administration Methods 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000002075 inversion recovery Methods 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 238000005304 joining Methods 0.000 description 1
• 150000002576 ketones Chemical class 0.000 description 1
• 230000008449 language Effects 0.000 description 1
• 239000000787 lecithin Substances 0.000 description 1
• 229940067606 lecithin Drugs 0.000 description 1
• 235000010445 lecithin Nutrition 0.000 description 1
• 210000000265 leukocyte Anatomy 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 229910052744 lithium Inorganic materials 0.000 description 1
• 238000002690 local anesthesia Methods 0.000 description 1
• 238000007422 luminescence assay Methods 0.000 description 1
• 239000006166 lysate Substances 0.000 description 1
• 239000012139 lysis buffer Substances 0.000 description 1
• 210000001161 mammalian embryo Anatomy 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 230000008774 maternal effect Effects 0.000 description 1
• 238000005374 membrane filtration Methods 0.000 description 1
• 230000008897 memory decline Effects 0.000 description 1
• 206010027175 memory impairment Diseases 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
• 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
• 238000001000 micrograph Methods 0.000 description 1
• 230000000877 morphologic effect Effects 0.000 description 1
• 230000007659 motor function Effects 0.000 description 1
• 239000012120 mounting media Substances 0.000 description 1
• 201000008383 nephritis Diseases 0.000 description 1
• 210000000653 nervous system Anatomy 0.000 description 1
• 230000001537 neural effect Effects 0.000 description 1
• 230000004770 neurodegeneration Effects 0.000 description 1
• 208000015122 neurodegenerative disease Diseases 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 230000016273 neuron death Effects 0.000 description 1
• 230000006764 neuronal dysfunction Effects 0.000 description 1
• 230000005015 neuronal process Effects 0.000 description 1
• 230000002981 neuropathic effect Effects 0.000 description 1
• 231100000189 neurotoxic Toxicity 0.000 description 1
• 230000003472 neutralizing effect Effects 0.000 description 1
• 229920001220 nitrocellulos Polymers 0.000 description 1
• 239000000346 nonvolatile oil Substances 0.000 description 1
• 229960002748 norepinephrine Drugs 0.000 description 1
• SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
• 239000003921 oil Substances 0.000 description 1
• 235000019198 oils Nutrition 0.000 description 1
• 239000002674 ointment Substances 0.000 description 1
• 229960005017 olanzapine Drugs 0.000 description 1
• KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 150000002895 organic esters Chemical class 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 230000036542 oxidative stress Effects 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 229940055729 papain Drugs 0.000 description 1
• 235000019834 papain Nutrition 0.000 description 1
• 230000005298 paramagnetic effect Effects 0.000 description 1
• 230000007310 pathophysiology Effects 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 230000010412 perfusion Effects 0.000 description 1
• 201000001245 periodontitis Diseases 0.000 description 1
• 230000008823 permeabilization Effects 0.000 description 1
• 235000020030 perry Nutrition 0.000 description 1
• 230000008782 phagocytosis Effects 0.000 description 1
• 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 239000011574 phosphorus Substances 0.000 description 1
• 230000035479 physiological effects, processes and functions Effects 0.000 description 1
• RMHMFHUVIITRHF-UHFFFAOYSA-N pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 description 1
• 229960004633 pirenzepine Drugs 0.000 description 1
• 239000002574 poison Substances 0.000 description 1
• 230000007096 poisonous effect Effects 0.000 description 1
• 229920000747 poly(lactic acid) Polymers 0.000 description 1
• 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 239000004626 polylactic acid Substances 0.000 description 1
• 238000003752 polymerase chain reaction Methods 0.000 description 1
• 108091033319 polynucleotide Proteins 0.000 description 1
• 102000040430 polynucleotide Human genes 0.000 description 1
• 239000002157 polynucleotide Substances 0.000 description 1
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
• 229920001282 polysaccharide Polymers 0.000 description 1
• 239000005017 polysaccharide Substances 0.000 description 1
• 229920001296 polysiloxane Polymers 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
• 108020001213 potassium channel Proteins 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 230000003518 presynaptic effect Effects 0.000 description 1
• 210000000063 presynaptic terminal Anatomy 0.000 description 1
• 230000003449 preventive effect Effects 0.000 description 1
• 238000011809 primate model Methods 0.000 description 1
• 230000004647 pro-inflammatory pathway Effects 0.000 description 1
• 239000001294 propane Substances 0.000 description 1
• 229960002934 propentofylline Drugs 0.000 description 1
• 235000019833 protease Nutrition 0.000 description 1
• 230000002685 pulmonary effect Effects 0.000 description 1
• 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
• 238000010791 quenching Methods 0.000 description 1
• 230000000171 quenching effect Effects 0.000 description 1
• 239000012217 radiopharmaceutical Substances 0.000 description 1
• 229940121896 radiopharmaceutical Drugs 0.000 description 1
• 230000002799 radiopharmaceutical effect Effects 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 238000010188 recombinant method Methods 0.000 description 1
• 210000000664 rectum Anatomy 0.000 description 1
• 230000011514 reflex Effects 0.000 description 1
• 230000002787 reinforcement Effects 0.000 description 1
• 230000008439 repair process Effects 0.000 description 1
• 238000003757 reverse transcription PCR Methods 0.000 description 1
• 206010039073 rheumatoid arthritis Diseases 0.000 description 1
• 229960001534 risperidone Drugs 0.000 description 1
• RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
• 239000011435 rock Substances 0.000 description 1
• 239000012266 salt solution Substances 0.000 description 1
• 150000003839 salts Chemical class 0.000 description 1
• 238000005070 sampling Methods 0.000 description 1
• 229920006395 saturated elastomer Polymers 0.000 description 1
• 238000013391 scatchard analysis Methods 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 210000000582 semen Anatomy 0.000 description 1
• 230000001953 sensory effect Effects 0.000 description 1
• 230000037152 sensory function Effects 0.000 description 1
• 238000013207 serial dilution Methods 0.000 description 1
• 206010040400 serum sickness Diseases 0.000 description 1
• 238000002603 single-photon emission computed tomography Methods 0.000 description 1
• 238000001542 size-exclusion chromatography Methods 0.000 description 1
• 231100000019 skin ulcer Toxicity 0.000 description 1
• 229910000029 sodium carbonate Inorganic materials 0.000 description 1
• FGCSIJPPCNCQJB-FAOVPRGRSA-M sodium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;chloride Chemical compound [Na+].[Cl-].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O FGCSIJPPCNCQJB-FAOVPRGRSA-M 0.000 description 1
• 239000002904 solvent Substances 0.000 description 1
• 210000004092 somatosensory cortex Anatomy 0.000 description 1
• 210000000278 spinal cord Anatomy 0.000 description 1
• 239000008174 sterile solution Substances 0.000 description 1
• 235000021286 stilbenes Nutrition 0.000 description 1
• 230000035882 stress Effects 0.000 description 1
• 229910052567 struvite Inorganic materials 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 229910052717 sulfur Inorganic materials 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• 239000000725 suspension Substances 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 102000013498 tau Proteins Human genes 0.000 description 1
• 108010026424 tau Proteins Proteins 0.000 description 1
• 210000003478 temporal lobe Anatomy 0.000 description 1
• 238000012876 topography Methods 0.000 description 1
• 239000013638 trimer Substances 0.000 description 1
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
• 239000012588 trypsin Substances 0.000 description 1
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
• 238000009827 uniform distribution Methods 0.000 description 1
• 229960005486 vaccine Drugs 0.000 description 1
• 238000001291 vacuum drying Methods 0.000 description 1
• 230000003156 vasculitic effect Effects 0.000 description 1
• 235000015112 vegetable and seed oil Nutrition 0.000 description 1
• 239000008158 vegetable oil Substances 0.000 description 1
• 230000035899 viability Effects 0.000 description 1
• 230000031836 visual learning Effects 0.000 description 1
• 238000012800 visualization Methods 0.000 description 1
• 235000019163 vitamin B12 Nutrition 0.000 description 1
• 239000011715 vitamin B12 Substances 0.000 description 1
• 230000003442 weekly effect Effects 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 230000003936 working memory Effects 0.000 description 1